Essa Pharma Stock Alpha and Beta Analysis

EPIX Stock  USD 1.60  0.01  0.62%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ESSA Pharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in ESSA Pharma over a specified time horizon. Remember, high ESSA Pharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ESSA Pharma's market risk premium analysis include:
Beta
(0.57)
Alpha
(1.16)
Risk
9.95
Sharpe Ratio
(0.11)
Expected Return
(1.12)
Please note that although ESSA Pharma alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, ESSA Pharma did 1.16  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of ESSA Pharma stock's relative risk over its benchmark. ESSA Pharma has a beta of 0.57  . As returns on the market increase, returns on owning ESSA Pharma are expected to decrease at a much lower rate. During the bear market, ESSA Pharma is likely to outperform the market. At this time, ESSA Pharma's Price Book Value Ratio is fairly stable compared to the past year. Price Fair Value is likely to rise to 49.54 in 2024, whereas Book Value Per Share is likely to drop 1.78 in 2024.

Enterprise Value

164.94 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out ESSA Pharma Backtesting, ESSA Pharma Valuation, ESSA Pharma Correlation, ESSA Pharma Hype Analysis, ESSA Pharma Volatility, ESSA Pharma History and analyze ESSA Pharma Performance.
For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

ESSA Pharma Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ESSA Pharma market risk premium is the additional return an investor will receive from holding ESSA Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ESSA Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ESSA Pharma's performance over market.
α-1.16   β-0.57

ESSA Pharma expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of ESSA Pharma's Buy-and-hold return. Our buy-and-hold chart shows how ESSA Pharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

ESSA Pharma Market Price Analysis

Market price analysis indicators help investors to evaluate how ESSA Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ESSA Pharma shares will generate the highest return on investment. By understating and applying ESSA Pharma stock market price indicators, traders can identify ESSA Pharma position entry and exit signals to maximize returns.

ESSA Pharma Return and Market Media

The median price of ESSA Pharma for the period between Tue, Sep 24, 2024 and Mon, Dec 23, 2024 is 1.83 with a coefficient of variation of 57.87. The daily time series for the period is distributed with a sample standard deviation of 2.14, arithmetic mean of 3.7, and mean deviation of 2.11. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Disposition of 50000 shares by Berger Franklin M of ESSA Pharma at 2.67 subject to Rule 16b-3
10/18/2024
2
ESSA Pharma Insiders Placed Bullish Bets Worth US709.0k
10/28/2024
3
ESSA Pharma tanks after terminating trial for its prostate cancer treatment
11/01/2024
4
Bb biotech ag sells Essa Pharma shares for 12 million
11/05/2024
5
EPIX ALERT Levi Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc.
11/14/2024
6
EPIX ACTIVE INVESTIGATION Contact Levi Korsinsky if you lost money on your ESSA Pharma Inc. investment
11/18/2024
7
Acquisition by Parkinson David Ross of 350000 shares of ESSA Pharma at 9.04 subject to Rule 16b-3
11/27/2024
8
Eikonizo Therapeutics Announces Investment by Novo Nordisk Advancing Lead Candidate EKZ-102 Toward Clinical Development
12/10/2024

About ESSA Pharma Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ESSA or other stocks. Alpha measures the amount that position in ESSA Pharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 (projected)
Net Current Asset Value770.5684.89
Days Payables Outstanding7.2K8.1K

ESSA Pharma Upcoming Company Events

As portrayed in its financial statements, the presentation of ESSA Pharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ESSA Pharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ESSA Pharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ESSA Pharma. Please utilize our Beneish M Score to check the likelihood of ESSA Pharma's management manipulating its earnings.
6th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
10th of December 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of September 2023
Last Financial Announcement
View

Build Portfolio with ESSA Pharma

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.